Epitalon vs MOTS-c: evidence, cost, and legality

Which is better, epitalon or MOTS-c?

Neither wins on evidence grade or regulatory status, because both are animal only and both are awaiting the same final FDA rule after the July 2026 PCAC vote. MOTS-c has the more independent and mechanistically detailed research base (AMPK activation, a human genetic variant linked to diabetes, exercise induced blood levels), which makes it the more defensible research interest for metabolic goals. Epitalon's lifespan data come from one mouse study in which mean life span did not change and from non-randomized human reports of a related extract. Neither should be expected to produce a clinical benefit. [2] [3] [5] [7] [8] [9]

How do epitalon and MOTS-c compare?

Epitalon and MOTS-c compared by dimension
Dimension	Epitalon	MOTS-c
Structure [1] [5]	Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a bovine pineal extract.	16 amino acid peptide encoded naturally by human mitochondrial DNA.
Proposed mechanism [1] [4] [5]	Induces telomerase (hTERT) and lengthens telomeres in human cell lines; proposed gene regulation and melatonin effects.	Inhibits the folate cycle, raises AICAR, and activates AMPK, increasing muscle glucose uptake and fat oxidation.
Strongest animal result [2] [5] [6]	In lifelong female SHR mice, longer life for the longest lived 10% and fewer spontaneous tumors, with no significant change in mean life span.	Prevented diet induced obesity and insulin resistance, improved insulin sensitivity in aged mice, and improved running capacity in young and old mice.
Human data [3] [6] [7]	Open, non-randomized reports from the developing institute in elderly patients, mostly using the pineal extract Epithalamin rather than synthetic epitalon.	Independent observational data: levels rise with exercise in young men; a MOTS-c sequence variant is associated with type 2 diabetes in Japanese men.
Theoretical safety concern [2] [5]	Telomerase activation could in theory support existing tumors, though mice had fewer tumors.	Could add to the glucose lowering of diabetes medications, based on mouse data.
Animal study dosing [2] [3] [5] [6]	0.1 ug per mouse subcutaneously in monthly 5 day courses; Russian human reports used 10 mg courses of the extract.	0.5 mg/kg per day intraperitoneally (metabolic) up to 15 mg/kg (exercise) in mice.
Note: No human dose has been established for either peptide.
Typical cost through a prescriber [8] [9]	No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price.	No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. MOTS-c has the same PCAC status as epitalon.
Note: PCAC's July 2026 recommendation for both is advisory until FDA publishes a final rule.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Epitalon and MOTS-c: grade, status, and cost
Attribute	Epitalon	MOTS-c
Class	Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract Epithalamin	Mitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA
What it is	4 amino acid peptide from a pineal gland extract: telomere and lifespan data in cells and mice, small non-randomized Russian human reports, not FDA approved.	A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.
Evidence	Evidence: Animal-only evidence	Evidence: Animal-only evidence
FDA status	Regulatory: Under FDA review	Regulatory: Under FDA review
Compounding	Epitalon was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding epitalon to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing.	MOTS-c was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding MOTS-c to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing.
WADA	WADA: WADA prohibited	WADA: WADA prohibited
Routes	Subcutaneous injection (as sold), Intramuscular injection (Russian Epithalamin reports), Intranasal and oral products exist without absorption data	Subcutaneous injection (as sold), Intraperitoneal injection (animal studies)
Typical cost	No lawful compounded price: Epitalon is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	No lawful compounded price: MOTS-c is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 22, 2026	Sep 27, 2026

Has epitalon been tested directly against MOTS-c?

No published trial has compared epitalon and MOTS-c directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do epitalon and MOTS-c cost?

Typical cost of Epitalon and MOTS-c
Dimension	Epitalon	MOTS-c
Typical cost	No lawful compounded price: Epitalon is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	No lawful compounded price: MOTS-c is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Epitalon price by channel	MOTS-c price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Are epitalon and MOTS-c legal to get with a prescription?

Both have the same status. FDA removed each from the 503A Category 2 list on April 15, 2026, and PCAC recommended adding both to the 503A bulks list on July 23 to 24, 2026. FDA had not published a final rule at verification, so state licensed 503A pharmacies vary in whether they will fill them. [8] [9]

Which one has better evidence for longevity?

Neither has human evidence for longevity. Epitalon extended life only in the longest lived tenth of female mice without changing mean life span, and MOTS-c improved physical capacity in old mice. Human data for both are observational. [2] [3] [6]

Which is more relevant for blood sugar or weight?

MOTS-c. It prevented diet induced obesity and insulin resistance in mice, and a human genetic variant that weakens it is associated with type 2 diabetes. Epitalon has not been studied for metabolic outcomes. No human treatment trial exists for either. [5] [7]

Are they banned in sport?

Yes. Both are prohibited at all times: epitalon under WADA section S0 as a non-approved substance, and MOTS-c under section S4.4, where it is named as a metabolic modulator. [10]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 27). Epitalon vs MOTS-c: evidence, cost, and legality. https://peptideagent.ai/compare/epitalon-vs-mots-c
HTML link: <a href="https://peptideagent.ai/compare/epitalon-vs-mots-c">Epitalon vs MOTS-c: evidence, cost, and legality</a>, PeptideAgent, updated September 27, 2026.

Epitalon vs MOTS-c

The short answer